The in vitro and in vivo disinclination of luminal breast cancer cells to AKT inhibitors is considerably mitigated by the pharmacological suppression of either BRD4/FOXO3A association or CDK6 (Figure 3) [51]. The gene discussed is BRD4; the disease is breast cancer.